Clonal evolution in chronic lymphocytic leukemia: Acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival

Haematologica

Volumn 92, Issue 9, 2007, Pages 1242-1245

  Stilgenbauer, Stephan ^a   Sander, Sandrine ^a   Bullinger, Lars ^a   Benner, Axel ^b   Leupolt, Elke ^a   Winkler, Dirk ^a   Kröber, Alexander ^a   Kienle, Dirk ^a   Lichter, Peter ^c   Döhner, Hartmut ^a  

^a UNIVERSITY OF ULM   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Molecular Genetics   (Germany)

Author keywords

CLL; Clonal evolution; Genetic instability; p53

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; FLUDARABINE; RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLONE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENOMICS; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS;

CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENOME, HUMAN; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; NEOPLASM STAGING; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 36349025291     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10720     Document Type: Article

References (29)

1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995; 1333:1052-7.
2. Chiorazzi N, Rai KR, Ferrarini M. Chronic Lymphocytic Leukemia. N Engl J Med 2005; 352:804-15.
3. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94:1840-7.
4. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94:1848-54.
5. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343:1910-6.
6. Kröber A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410-6.
7. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100:1177-84.
8. Han T, Ohtaki K, Sadamori N, et al. Cytogenetic evidence for clonal evolution in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 1986; 23:321-8.
9. Nowell PC, Moreau L, Growney P, Besa EC. Karyotypic stability in chronic B-cell leukemia. Cancer Genet Cytogenet 1988; 33:155-60.
10. Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990;323:720-4.
11. Oscier D, Fitchett M, Hergert T, Lambert R. Karyotypic evolution in B-cell chronic lymphocytic leukaemia. Genes, Chromosomes & Cancer 1991; 3:16-20.
12. Raghoebier S, Kibbelaar RE, Kleiverda K, et al. Mosaicism of trisomy 12 in chronic lymphocytic leukemia detected by non-radioactive in situ hybridisation. Leukemia 1992; 6:1220-6.
13. Escudier SM, Pereira-Leahy JM, Drach JW, et al. Fluorescence in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia. Blood 1993; 81:2702-7.
14. Cuneo A, Bigoni R, Balboni M, et al. Trisomy 12 in chronic lymphocytic leukemia and hairy cell leukemia: a cytogenetic and interphase cytogenetic study. Leuk Lymphoma 1994;15:167-72.
15. Auer RL, Bienz N, Neilson J, et al. The sequential analysis of trisomy 12 in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999; 104:742-4.
16. Hjalmar V, Hast R, Kimby E. Sequential fluorescence in situ hybridization analyses for trisomy 12 in chronic leukemic B-cell disorders. Haematologica 2001; 86:174-180.
17. Chevallier P, Penther D, Avet-Loiseau H, et al. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol 2002; 116:142-50.
18. Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006;24:437-43.
19. Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006;24:4634-41.
20. Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007;25:799-804.
21. Pfeifer D, Pantic M, Skatulla I, Rawluk J, Kreutz C, Martens UM, et al. Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood 2007;109:1202-10.
22. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete conservations. J Am Stat Ass 1958; 53:457-81.
24. Andersen P, Gill R. Cox's regression model for counting processes, a large sample study. Ann Stat 1982;10:1100-12.
25. R Development Core Team. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2006. ISBN 3-900051-07-0, URL http://www.R-project.org.
26. Mertens D, Wolf S, Tschuch C, et al. Allelic silencing at the tumor-suppressor locus 13q14.3 suggests an epigenetic tumor-suppressor mechanism. Proc Natl Acad Sci USA 2006;103:7741-6.
27. Döhner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and nonresponse to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85:1580-9
28. El Rouby S, Thomas A, Costin D, et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993; 82:3452-9.
29. Geisler CH, Philip P, Egelund Christensen B, et al. In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: A cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients. Leuk Res 1997; 21:1011-23.